← Back to Clinical Trials
Recruiting Phase 1 NCT07053917

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

Trial Parameters

Condition Stroke
Sponsor Johns Hopkins University
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 20
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2026-02-09
Completion 2027-02
Interventions
Psilocybin (Usona Institute)

Brief Summary

The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.

Eligibility Criteria

Inclusion Criteria: * Over age 18 years, inclusive. * Ischemic or hemorrhagic stroke confirmed by CT or MRI, at least 12 months prior to admission date * Ability to give informed consent and understand the tasks involved. * Agree that, for the study duration, will refrain from: (1) No new prescription medications during the time of the study without approval of the study team, (2) taking any herbal supplement (except with prior approval of the research team), (3) taking any nonprescription medications with the exception of: 1. non-steroidal anti-inflammatory drugs. 2. acetaminophen. 3. vitamins. 4. or other over-the-counter medications approved by the research team * Are willing to follow restrictions and guidelines concerning medications, consumption of food, beverages, and nicotine the night before and just prior to psilocybin administration. * Agree to have transportation other than driving themselves home or to where the participants are staying after the administration of psilocyb

Related Trials